Daily Dose Q&A
2026-03-24
Provide some reasons why the effects of cannabinoids vary among individuals. 
There are many reasons why the effects of cannabinoids vary among individuals. SOME of the reasons are: diet, age, health of the patient, and co-administered medications may impact metabolism and efficacy of cannabinoid-based products. Also, some patients have a genetic profile such that they are predisposed to experience side effects (for ex., exacerbation of a psychotic disorder/schizophrenia) after exposure to THC. In addition, patients that have been consuming cannabinoid-based products long-term react differently than patients who have never consumed cannabinoid-based products. Grotenhermen F. Clinical pharmacokinetics of cannabinoids. J Cannabis Ther, 2003; 3(1): 3-51. https://www.tandfonline.com/doi/abs/10.1300/J175v03n01_02. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770-804. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689518/
2026-03-23
Even if an individual employs the same mode of administration over time, the effects of cannabinoids may change for that individual. Provide some reasons why this may be so.
The effects of cannabinoids may change over time due to multiple factors, including: 1. tolerance to the cannabinoids may develop 2. change in the patient's health status/ medical condition may change over time and lead to physiological changes in the endocannabinoid system (For example, inflammation impacts the ECS. Also, impaired G.I./liver function affects the absorption and metabolism of cannabinoids.) 3. The patient may start or stop taking a medication that interacts with cannabinoids or affects the metabolism of the cannabinoid-based product. 4. Physiologic changes in the endocannabinoid system take place as patients age.Grotenhermen F. Clinical pharmacokinetics of cannabinoids. J Cannabis Ther, 2003; 3(1): 3-51. https://www.tandfonline.com/doi/abs/10.1300/J175v03n01_02. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770-804. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689518/
2026-03-20
Marijuana use has been associated with an impairment of spermatogenesis and testicular function. How long will those effects last?
It has been reported that recovery of spermatogenesis and testicular cell function s/p exposure to marijuana is approximately about 45 days. Meah F, Lundholm M, Emanuele N, Amjed H, Poku C, Agrawal L, Emanuele MA. The effects of cannabis and cannabinoids on the endocrine system. Rev Endocr Metab Disord. 2022 Jun;23(3):401-420. doi: 10.1007/s11154-021-09682-w. Epub 2021 Aug 30. PMID: 34460075.
2026-03-19
Do cannabinoids affect the male reproduction system?
Yes. Cannabinoid receptors are located in multiple parts of the male reproductive system, including the hypothalamus, pituitary, Leydig cells, and sperm. The binding of cannabinoids to cannabinoid 1 receptors may lead to a reduction in plasma testosterone, LH and FSH. Meah F, Lundholm M, Emanuele N, Amjed H, Poku C, Agrawal L, Emanuele MA. The effects of cannabis and cannabinoids on the endocrine system. Rev Endocr Metab Disord. 2022 Jun;23(3):401-420. doi: 10.1007/s11154-021-09682-w. Epub 2021 Aug 30. PMID: 34460075.
2026-03-18
On April 6, 2020, the DEA removed Epidiolex (an FDA-approved CBD product) from Schedule V and de-scheduled it entirely. How does the descheduling impact the prescribing of this CBD product?
The descheduling means that Epidiolex is no longer subject to the Controlled Substances Act and its tracking and monitoring requirements. In other words, prescriptions for Epidiolex, like other non-controlled medicines, will be valid for one year and can be easily transferred between pharmacies. The de-scheduling of Epidiolex also enables physicians to prescribe this breakthrough medicine free of the requirements of state prescription drug monitoring programs.GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance
https://www.globenewswire.com/news-release/2020/04/06/2012160/0/en/GW-Pharmaceuticals-plc-and-Its-U-S-Subsidiary-Greenwich-Biosciences-Inc-Announce-That-EPIDIOLEX-cannabidiol-Oral-Solution-Has-Been-Descheduled-And-Is-No-Longer-A-Controlled-Substan.html